Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.

Hjort MA, Hov H, Abdollahi P, Vandsemb EN, Fagerli UM, Lund B, Slørdahl TS, Børset M, Rø TB.

Exp Hematol Oncol. 2018 Apr 10;7:8. doi: 10.1186/s40164-018-0100-2. eCollection 2018.

2.

Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects.

Yang X, Feng W, Wang R, Yang F, Wang L, Chen S, Ru Y, Cheng T, Zheng G.

Oncoimmunology. 2017 Dec 26;7(4):e1412910. doi: 10.1080/2162402X.2017.1412910. eCollection 2018.

PMID:
29632729
3.

Targeting Macrophages in Cancer: From Bench to Bedside.

Poh AR, Ernst M.

Front Oncol. 2018 Mar 12;8:49. doi: 10.3389/fonc.2018.00049. eCollection 2018. Review.

4.

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Menter T, Tzankov A.

Front Oncol. 2018 Mar 7;8:54. doi: 10.3389/fonc.2018.00054. eCollection 2018. Review.

5.

Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?

Parisi L, Gini E, Baci D, Tremolati M, Fanuli M, Bassani B, Farronato G, Bruno A, Mortara L.

J Immunol Res. 2018 Jan 14;2018:8917804. doi: 10.1155/2018/8917804. eCollection 2018. Review.

6.

CONCORD biomarker prediction for novel drug introduction to different cancer types.

Kim Y, Dillon PM, Park T, Lee JK.

Oncotarget. 2017 Dec 9;9(1):1091-1106. doi: 10.18632/oncotarget.23124. eCollection 2018 Jan 2.

7.

Cancer immunology and melanoma immunotherapy.

Linck RDM, Costa RLP, Garicochea B.

An Bras Dermatol. 2017 Nov-Dec;92(6):830-835. doi: 10.1590/abd1806-4841.201756511. Review.

8.

Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.

Chen X, Chen J, Zhang W, Sun R, Liu T, Zheng Y, Wu Y.

Oncotarget. 2017 Nov 9;8(68):112685-112696. doi: 10.18632/oncotarget.22340. eCollection 2017 Dec 22.

9.

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Merryman RW, Armand P, Wright KT, Rodig SJ.

Blood Adv. 2017 Dec 12;1(26):2643-2654. doi: 10.1182/bloodadvances.2017012534. eCollection 2017 Dec 12. Review.

10.

High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Hollander P, Kamper P, Smedby KE, Enblad G, Ludvigsen M, Mortensen J, Amini RM, Hamilton-Dutoit S, d'Amore F, Molin D, Glimelius I.

Blood Adv. 2017 Aug 8;1(18):1427-1439. doi: 10.1182/bloodadvances.2017006346. eCollection 2017 Aug 8.

11.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

12.

Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.

Mikkilineni L, Whitaker-Menezes D, Domingo-Vidal M, Sprandio J, Avena P, Cotzia P, Dulau-Florea A, Gong J, Uppal G, Zhan T, Leiby B, Lin Z, Pro B, Sotgia F, Lisanti MP, Martinez-Outschoorn U.

Semin Oncol. 2017 Jun;44(3):218-225. doi: 10.1053/j.seminoncol.2017.10.003. Epub 2017 Oct 10.

PMID:
29248133
13.

Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Hoeres T, Wilhelm M, Smetak M, Holzmann E, Schulze-Tanzil G, Birkmann J.

Clin Exp Immunol. 2018 Apr;192(1):54-67. doi: 10.1111/cei.13090. Epub 2018 Jan 4.

PMID:
29235095
14.

Evaluation of Tumour Associated Macrophages and Angiogenesis in Ameloblastoma.

Adisa AO, Udeabor SE, Orlowska A, Sader RA, Ghanaati S.

J Clin Diagn Res. 2017 Sep;11(9):ZC33-ZC35. doi: 10.7860/JCDR/2017/28067.10568. Epub 2017 Sep 1.

15.

Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study.

Zhang Y, Zhang J, Zeng H, Zhou XH, Zhou HB.

Oncotarget. 2017 Oct 9;8(54):92978-92988. doi: 10.18632/oncotarget.21722. eCollection 2017 Nov 3.

16.

Clinical Significance of CD163+ and CD68+ Tumor-associated Macrophages in High-risk HPV-related Cervical Cancer.

Chen XJ, Han LF, Wu XG, Wei WF, Wu LF, Yi HY, Yan RM, Bai XY, Zhong M, Yu YH, Liang L, Wang W.

J Cancer. 2017 Oct 17;8(18):3868-3875. doi: 10.7150/jca.21444. eCollection 2017.

17.

Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.

Kitano Y, Okabe H, Yamashita YI, Nakagawa S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K, Kaida T, Miyata T, Mima K, Imai K, Hashimoto D, Komohara Y, Chikamoto A, Ishiko T, Baba H.

Br J Cancer. 2018 Jan;118(2):171-180. doi: 10.1038/bjc.2017.401. Epub 2017 Nov 9.

PMID:
29123259
18.

Clinical significance of tryptophan catabolism in Hodgkin lymphoma.

Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S.

Cancer Sci. 2018 Jan;109(1):74-83. doi: 10.1111/cas.13432. Epub 2017 Nov 29.

19.

Management of penile cancer in a Singapore tertiary hospital.

Tan TW, Chia SJ, Chong KT.

Arab J Urol. 2017 Mar 30;15(2):123-130. doi: 10.1016/j.aju.2017.03.001. eCollection 2017 Jun.

20.

Cell-to-cell communication: microRNAs as hormones.

Bayraktar R, Van Roosbroeck K, Calin GA.

Mol Oncol. 2017 Dec;11(12):1673-1686. doi: 10.1002/1878-0261.12144. Epub 2017 Oct 26. Review.

Supplemental Content

Support Center